Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Mutations in the Extracellular Amino-terminal Domain of the NK2
Neurokinin Receptor Abolish cAMP Signaling but Preserve Intracellular
Calcium Responses*
Sandra
Lecat§,
Bernard
Bucher¶,
Yves
Mely¶, and
Jean-Luc
Galzi
From CNRS UPR9050, Récepteurs et
Protéines Membranaires, Ecole Supérieure de Biotechnologie
de Strasbourg, Boulevard Sébastien Brandt, Illkirch 67400, France
and ¶ CNRS UMR7034 Pharmacologie et Physicochimie des Interactions
Cellulaires et Moléculaires, Université Louis Pasteur de
Strasbourg, Faculté de Pharmacie 74, Route du Rhin,
Illkirch BP 24 67401, France
By combining real time measurements of agonist
binding, by fluorescence resonance energy transfer, and of subsequent
responses,we proposed previously that the neurokinin NK2 receptor
preexistsin equilibrium between three states: inactive,
calcium-triggering,and cAMP-producing. Thr24 and
Phe26 of the NK2 receptor extracellular domain are
considered to interactwith neuropeptide agonists based on the
reduction of affinitywhen they are substituted by alanine. Using
fluorescence resonanceenergy transfer, we now quantify the binding
kinetics of two TexasRed-modified neurokinin A agonists to the
fluorescent wild-type(Y-NK2wt) and the mutant (Y-NK2mut)
receptor carrying Thr24 Ala and Phe26 Ala mutations. TR1-neurokinin A binds with a fast componentand a slow
component to the Y-NK2wt receptor and triggers botha calcium and a
cAMP response. In contrast, on the mutant receptor,it binds in a
single fast step with a lower apparent affinityand activates only the
calcium response. Another agonist, TRC4-neurokininA, binds to both
wild-type and mutant receptors in a single faststep, with similar
affinities and kinetics and promotes only calciumsignaling. Kinetic
modeling of ligand binding and receptor interconversionsis carried out
to analyze phenotypic changes in terms of bindingalterations or
changes in the transitions between conformationalstates. We show that
the binding and response properties of theY-NK2mut
receptor are best described according to a phenotypewhere a reduction
of the transition between the inactive and theactive statesoccurs.
Pirenzepine Promotes the Dimerization of Muscarinic M1 Receptors through a Three-step Binding Process.
B. Ilien, N. Glasser, J.-P. Clamme, P. Didier, E. Piemont, R. Chinnappan, S. B. Daval, J.-L. Galzi, and Y. Mely (2009)
J. Biol. Chem.
284, 19533-19543
|Abstract »|Full Text »|PDF »
Organic Anion Transporter OAT1 Undergoes Constitutive and Protein Kinase C-regulated Trafficking through a Dynamin- and Clathrin-dependent Pathway.
Q. Zhang, M. Hong, P. Duan, Z. Pan, J. Ma, and G. You (2008)
J. Biol. Chem.
283, 32570-32579
|Abstract »|Full Text »|PDF »
A Novel Biological Role of Tachykinins as an Up-Regulator of Oocyte Growth: Identification of an Evolutionary Origin of Tachykininergic Functions in the Ovary of the Ascidian, Ciona intestinalis.
M. Aoyama, T. Kawada, M. Fujie, K. Hotta, T. Sakai, T. Sekiguchi, K. Oka, N. Satoh, and H. Satake (2008)
Endocrinology
149, 4346-4356
|Abstract »|Full Text »|PDF »
Post-activation-mediated Changes in Opioid Receptors Detected by N-terminal Antibodies.
A. Gupta, R. Rozenfeld, I. Gomes, K. M. Raehal, F. M. Decaillot, L. M. Bohn, and L. A. Devi (2008)
J. Biol. Chem.
283, 10735-10744
|Abstract »|Full Text »|PDF »
Changes in angiotensin II type 1 receptor signalling pathways evoked by a monoclonal antibody raised to the N-terminus.
F. Xiao, J. R Puddefoot, S. Barker, and G. P Vinson (2008)
J. Endocrinol.
197, 25-33
|Abstract »|Full Text »|PDF »
Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor.
M A Redondo-Muller, M Stevanovic-Walker, S Barker, J R Puddefoot, and G P Vinson (2008)
Endocr. Relat. Cancer
15, 277-288
|Abstract »|Full Text »|PDF »
A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties.
E. L. Maillet, N. Pellegrini, C. Valant, B. Bucher, M. Hibert, J.-J. Bourguignon, and J.-L. Galzi (2007)
FASEB J
21, 2124-2134
|Abstract »|Full Text »|PDF »
Conformation State-sensitive Antibodies to G-protein-coupled Receptors.
A. Gupta, F. M. Decaillot, I. Gomes, O. Tkalych, A. S. Heimann, E. S. Ferro, and L. A. Devi (2007)
J. Biol. Chem.
282, 5116-5124
|Abstract »|Full Text »|PDF »
Serotonin (5-HT) Receptor Subtypes Mediate Specific Modes of 5-HT-Induced Signaling and Regulation of Neurosecretion in Gonadotropin-Releasing Hormone Neurons.
K. Wada, L. Hu, N. Mores, C. E. Navarro, H. Fuda, L. Z. Krsmanovic, and K. J. Catt (2006)
Mol. Endocrinol.
20, 125-135
|Abstract »|Full Text »|PDF »
Dynamic Confinement of NK2 Receptors in the Plasma Membrane: IMPROVED FRAP ANALYSIS AND BIOLOGICAL RELEVANCE.
L. Cezanne, S. Lecat, B. Lagane, C. Millot, J.-Y. Vollmer, H. Matthes, J.-L. Galzi, and A. Lopez (2004)
J. Biol. Chem.
279, 45057-45067
|Abstract »|Full Text »|PDF »
Minireview: Diversity and Complexity of Signaling through Peptidergic G Protein-Coupled Receptors.
A. J. Rashid, B. F. O'Dowd, and S. R. George (2004)
Endocrinology
145, 2645-2652
|Abstract »|Full Text »|PDF »